Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) have revolutionized the management of many types of solid tumors, including metastatic renal cell carcinoma (mRCC). Both sequential and combinatorial therapeutic strategies utilizing anti-PD-1 monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liguori, Luigi, Luciano, Angelo, Polcaro, Giovanna, Ottaiano, Alessandro, Cascella, Marco, Perri, Francesco, Pepe, Stefano, Sabbatino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669217/
https://www.ncbi.nlm.nih.gov/pubmed/38001973
http://dx.doi.org/10.3390/biomedicines11112974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669217/
https://www.ncbi.nlm.nih.gov/pubmed/38001973
http://dx.doi.org/10.3390/biomedicines11112974

Ejemplares similares